AZ304

Catalog No.S8755 Batch:S875501

Print

Technical Data

Formula

C27H25N5O2
Molecular Weight 451.52 CAS No. 942507-42-8
Solubility (25°C)* In vitro DMSO 90 mg/mL (199.32 mM)
Ethanol 5 mg/mL (11.07 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description AZ304 is a synthetic inhibitor designed to interact with the ATP-binding site of wild type and V600E mutant BRAF with IC50 values of 79 nM and 38 nM, respectively. It also inhibits CRAF, p38 and CSF1R at sub 100 nM potencies.
Targets
p38 [1]
(Cell-free assay)		 CSF1R [1]
(Cell-free assay)		 BRAF(V600E) [1]
(Cell-free assay)		 CRAF [1]
(Cell-free assay)		 WT BRAF [1]
(Cell-free assay)
6 nM 35 nM 38 nM 68 nM 79 nM
In vitro

AZ304 shows potent inhibitory activities to the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF in vitro, with IC50 values of 79 nM, 38 nM and 68 nM, respectively. AZ304 potently reduces ERK phosphorylation (p-ERK), with a mean EC50 of 65 nM in the V600E mutant BRAF containing melanoma cell line A375 and an EC50 of 60 nM in the wild type BRAF containing melanoma cell line SK-MEL-31. AZ304 markedly inhibits cell proliferation in mutant BRAF cancer cell lines, and effectively reduces cell growth in selected cell lines harbouring wild type BRAF/RAS or mutant RAS. The GI50 values ranged from 0.08-7.72 μM in mutant BRAF cell lines, 0.43-11.7 μM in wild type BRAF/RAS cell lines, and 0.9-16.66 μM in mutant RAS cell lines. AZ304 exhibits anti-proliferative effects on multiple cancer types, including melanoma, colorectal cancer, leukaemia, ovarian cancer, lung cancer, and pancreatic cancer, independently of BRAF genetic status. AZ304 retains inhibitory activity against both V600E mutant and wild type BRAF CRC cell lines in the presence of the EGFR ligand EGF[1].
In vivo

AZ304 monotherapy and its combination with Cetuximab have anti-tumour effects on RKO and Caco-2 tumour xenografts without obvious toxicity, independently of BRAF mutation status[1].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    cell lines containing wild type BRAF or V600E mutant BRAF (MC-F7, A549 and A375 cells)

  • Concentrations

    6.5 nM, 65 nM, 650 nM and 6.5 μM

  • Incubation Time

    75 min

  • Method

    In vitro p-ERK and p-P38 evaluation in cell lines containing wild type BRAF or V600E mutant BRAF: Cells are collected following 75 min treatment at 0.1, 1, 10 and 100 fold of A375 p-ERK EC50 for each compound. (A375: BRAF V600E, A549: RAS MT; MC-F7: BRAF/RAS WT)
Animal Study:

[1]
  • Animal Models

    Female 4-6 weeks old athymic BALB/c nude mice inoculated with RKO/Caco-2 cells

  • Dosages

    10 mg/kg

  • Administration

    by oral gavage

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.